about
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersImplications of NRAS mutations in AML: a study of 2502 patients.Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaOutcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.Older patients with myeloma derive similar benefit from autologous transplantation.Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.Molecular diagnostics in acute leukemias.CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cellsRare cytogenetic abnormalities in myelodysplastic syndromes.Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARAMyelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challengesMolecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?The benefit of population-based studies for older patients with acute myeloid leukemiaInsight into the molecular pathogenesis of myeloid malignancies.Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisUse of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationDetection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.Discussion of the applicability of microarrays: profiling of leukemias.Current status of gene expression profiling in the diagnosis and management of acute leukaemia.Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.Safety of conditioning agents for allogeneic haematopoietic transplantation.Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.Gene expression profiling in acute myeloid leukaemia (AML).Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.Molecular genetics in acute myeloid leukemia.
P50
Q24675681-FD04C63F-A45B-4F9C-A549-4732FFB32018Q27824859-ECCF66F7-AE58-4721-BDCF-F5BC01B2A784Q27851417-BA2802B2-FC6A-454E-B5F5-13A86A732802Q28307278-F9C480B9-1D8F-426B-B98A-D1E62BCD439DQ30252975-2D48DC12-EB63-4093-BF12-284E38C7A23BQ30317754-8449F4D6-53FF-4F4B-99B9-7AC348A97A9BQ30370038-5732E089-F9A7-4887-8AF6-3BE50A521B1FQ33383573-41DE7E9D-D455-48FB-95F7-B063DF04DB78Q33649332-50DDAACE-4725-4451-9C33-5E1F5DE09654Q33756719-EA5BA8D3-97BB-486F-B82F-9377E278FBA8Q33878649-72B3A994-E119-44CF-8A0D-5A5D30117C3AQ34240314-64D6CF14-4702-4995-81FC-E8D198CBFC12Q34295164-C9CAE4FF-2CEA-4113-BA8B-B2F94B04DD96Q35007333-699243B2-D493-49A8-AD13-A3774FB8D11BQ35018518-DCF1F979-7EEE-4340-8D88-1F36D853D577Q35193722-52140DB8-338F-498D-A792-BF6A8879665BQ35565387-08F9F9FC-386A-43EC-8AF0-6A9986DA9CC2Q35596919-4F2C82C5-D1C1-444C-B111-0017F1BD38C7Q36266642-8BB56926-614B-427D-B0D6-B8EC9CDF9E5EQ36366973-49583703-D27F-44CB-8FFB-D15CA4B6A3D3Q36410168-1A253895-2BD8-4697-B2A5-5CE20C62CA27Q36662009-1E05904A-480B-4C0E-9B99-1995EF5F0DA4Q36719203-B69BE8CF-A43B-49C3-848D-0C7CF4300EB6Q36765475-4092E9CB-025D-4383-9604-8332FB96E9FFQ36928803-EBE669F0-B28D-4C87-BF6F-0C2A3EB1E224Q36936505-AA2FF26E-0A62-4DF2-9FF6-217D09F2BEFCQ37083601-08F6CDAC-402E-4241-BC66-5FEFA72C3D03Q37112871-9783AD66-38D6-46A9-8318-4178397AFFF1Q37332638-67D4F3CC-188E-41A3-B002-720405CA051DQ37391398-C8926425-6E03-4227-B8DE-EE686C87AE6CQ37432236-1FE11701-54F9-4FB5-8DFA-520269809D04Q37497800-C805C454-3080-4B8C-B7B5-CD66F5D090DDQ37510948-3B8BD0DE-356B-4D29-B52E-B94F4052D98BQ37559330-5B53D471-7A89-49E4-8138-BD7E8CC9652DQ37584250-97FA149B-1628-4EC0-8353-5216D6945E67Q37594993-AA0A5CBB-7A82-4377-8EF4-499BF49EA3F2Q37669460-A852EF7C-DBF3-40D6-B351-68C6DBBC2F68Q37701292-D26DAA0D-B3A2-433B-A9E7-4F86B54F9830Q37767035-6A8CD118-F0F0-4DB4-850B-55BE3A777B4AQ37784131-765A68DC-8A38-4334-AC97-2E468277AD92
P50
name
Ulrike Bacher
@ast
Ulrike Bacher
@en
Ulrike Bacher
@nl
type
label
Ulrike Bacher
@ast
Ulrike Bacher
@en
Ulrike Bacher
@nl
prefLabel
Ulrike Bacher
@ast
Ulrike Bacher
@en
Ulrike Bacher
@nl